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Abstract
Background: Kawasaki disease (KD) is a form of self-limiting vasculitis that causes coronary artery abnormality in
children. Based on reports of elevated plasma level of cytokines such as tumor necrosis factor-α in KD patients,
clinical trials of monoclonal antibodies that block cytokine cascades have been conducted. However, the studies
have revealed contradictory results. The objective of this study is to examine the effectiveness of treatment with
monoclonal antibodies for KD patients.
Methods: Relevant randomized controlled trials (RCTs), cluster RCTs, quasi-RCTs, cross-over trials, and any
observational studies (e.g., cohort studies, case-control studies, case series, and case reports) will be included
to summarize available evidence both qualitatively and quantitatively. Cochrane Central Register of Controlled
Trials, MEDLINE, EMBASE, and ICUSHI will be searched. We will assess coronary artery and treatment outcomes
of the interventions. Two authors will independently screen studies for inclusion and consulting with a third
author where necessary to resolve discrepancies. The risk of bias of included studies will be assessed using
the Cochrane Collaboration risk of bias tool and quality of evidence using the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach. Meta-analysis of the included studies will be
conducted using fixed effects or random effects models depending on the degree of between-study heterogeneity.
Results will be presented using risk ratios with 95 % confidence interval (CI) for dichotomous outcomes and
standardized mean differences with 95 % CI for continuous outcomes.
Discussion: This systematic review and meta-analysis protocol does not require ethical approval. We will
disseminate the findings of this systematic review and meta-analysis via publications in peer-reviewed journals.
Trial registration: PROSPERO CRD42016033079.
Keywords: Kawasaki disease, Monoclonal antibody agents, Coronary artery abnormality, Meta-analysis,
Systematic review
Introduction
Kawasaki disease (KD) is a self-limiting form of vascu-
litis of unknown cause and is a major cause of acquired
heart disease in developed countries [1]. KD was origin-
ally described in 1967 by Tomisaku Kawasaki and mainly
affects children less than 5 years of age, with peak onset
between 10 and 12 months [2, 3]. The incidence of KD
in children younger than 5 years old varies; 239.6 per
100,000 in Japan, 17.1 per 100,000 in the USA, and 8.1
per 100,000 in the UK [4]. Diagnosis of KD is generally
based on the clinical signs and symptoms described in
either of the two major sets of criteria. The diagnostic
guidelines of the Japan KD Research Committee require
any five signs or symptoms including (1) fever longer
than 5 days, (2) bulbar nonexudative conjunctival injec-
tion [5] and cervical lymphadenopathy, (4) polymorph-
ous rash, (5) oral and perioral changes, and (6) extremity
changes [6].
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Although the cause of KD is still unknown, the main
pathophysiology has been found to be associated with
systemic vasculitis, particularly affecting coronary arteries,
which leads to the development of coronary artery aneu-
rysms (CAAs) in 15–25 % of untreated patients. About 2–
3 % of untreated KD cases die as a result of coronary
vasculitis [3]. Therefore, there has been intense interest in
treatments to reduce the risk of CAAs. KD is also poten-
tially an important cause of long-term cardiac diseases in
adult life. Treatment of acute stage KD with aspirin and
intravenous immunoglobulin (IVIG) has been established
as a standard initial therapy, which has been shown to
limit the duration of the acute phase of KD, as well as
reducing the incidence of long-term coronary event from
25 % to less than 3 % [7, 8]. However, about 20 % of
patients had persistent or recurrent fever after completion
of IVIG, together with a particularly high risk of develop-
ing CAAs [9]. Therefore, intensification of the initial ther-
apy and second-line therapy has been the focus of clinical
research for acute phase treatment of KD.
Currently, there are reports on the elevation of plasma
levels of a variety of multiple inflammatory cytokines,
such as tumor necrosis factor-α (TNF-α), interleukin
(IL)-1b, IL-6, and IL-8 during the acute phase of KD
[10]. Among these cytokines, TNF-α was found to play
an important role in the development of coronary artery
lesions in mouse models of KD [11]. Clinical trials of
TNF-α-related biologics such as infliximab and etaner-
cept as an initial or additional rescue therapy for refrac-
tory KD patients yielded contradictory results [12–14].
Moreover, studies on treatments with other monoclonal
antibodies such as anakinra, tocilizumab, and rituximab
are limited to case reports or case series [15–18]. Taken
together, these studies suggest that the effectiveness of
monoclonal antibody therapeutic agents for acute KD
remain undetermined. To that end, we will conduct a
systemic review and meta-analysis to summarize the evi-
dence of the potential effectiveness and safety of mono-
clonal antibodies as a treatment option for KD patients.
Objectives
The main objective of this systematic review is to evaluate
the effectiveness of monoclonal antibodies as therapeutic
agents for KD patients. We will investigate the effective-
ness of initial or additional treatment with monoclonal
antibodies for KD patients towards the incidence of CAAs
or patients who need additional rescue therapy, compared




Our systematic review and meta-analysis will include
randomized control trials (RCTs) and cluster RCTs,
quasi-RCTs, cross-over trials, and any observational stud-
ies (e.g., cohort studies, case-control studies, case series,
and case reports).
This protocol is registered with PROSPERO
(International prospective register of systematic re-
views) at the National Institute for Health Research and
Centre for Reviews and Dissemination (CRD), University
of York (registration number: CRD42016033079).
Types of participants
We will include all patients diagnosed with KD globally
in the analysis. The diagnosis of KD includes both
complete and incomplete KD and must fulfill the diag-
nostic guidelines of the Japan KD Research Committee
or the American Heart Association guidelines [7, 19].
Types of intervention
All forms of monoclonal antibody therapies in conjunc-
tion with any combination of placebo or no treatment,
IVIG, aspirin, or corticosteroid for the treatment of KD
will be considered as the intervention of interest.
Types of outcome measures
Primary outcomes
1. Coronary artery abnormalities.
The incidence of aneurysmal coronary abnormalities
(measured via diameter or z-scores) per study
group found at either coronary angiogram or
echocardiography within 3 months of KD diagnosis.
The definition of coronary abnormality was defined by
either the Z-score (a coronary dimension that is ≥2.5
standard deviations (SDs) above the mean for that
body surface area) or the Japanese Ministry of Health
criteria [20]:
(a)Lumen >3 mm in children <5 years old;
(b)Lumen >4 mm in children >5 years old;
(c) Internal diameter of a segment measuring ≥1.5
times that of an adjacent segment.
2. Treatment resistance.
Treatment resistance is defined as a clinical state of
non-responding to an initial therapy.
Secondary outcomes
1. Duration of fever (days)
2. Length of hospital stay (days)
3. Time for biochemical parameters to normalize: CRP
and ESR
4. Incidence of adverse event (for example, fever,
coronary artery abnormalities, headache, and
hemolytic anemia)
5. The incidence of any adverse event per study group
that is attributable to the administration of monoclonal
antibodies at any point after treatment initiation
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Electronic searches
We will conduct the systematic review and meta-
analysis according to the Cochrane Handbook for Sys-
tematic Reviews of Interventions and the Meta-analysis
of Observational Studies in Epidemiology (MOOSE)
census statement. This protocol follows the Preferred
Reporting Items for Systematic Review and Meta-
Analysis Protocols 2015 (Additional file 1) [21].
A comprehensive literature review using the database
of the Ovid platform including MEDLINE, EMBASE
plus EMBASE classics and Cochrane Central Register of
Controlled Trials, and ICHUSHI (research database in
Japanese conducted by the Japan Medical Abstracts
Society) will be performed. Literature search strategies
will be developed using medical subject headings
(MeSH) and text related to “Kawasaki disease” and
“monoclonal antibody.” We will include all languages in
our searches. Our search strategy will be reviewed by an
experienced librarian at the National Center for Child
Health and Development. Additional file 2 shows the
search strategy in more detail.
Searching other resources
The International Clinical Trials Registry Platform
Search Portal, ClinicalTrials.gov, and UMIN-CTR will be
searched for ongoing or recently completed trials.
Data collection and analysis
– Eligible criterion
1. Studies which examined the efficacy and/or
safety of monoclonal antibodies (e.g., infliximab,
etanercept, rituximab, anakinra, and tocilizumab)
for patients with KD.
– Ineligible criteria
1. Experimental studies (in vivo study)
2. Studies with no relationship with Kawasaki
disease
3. Studies with no relationship with monoclonal
antibodies
4. Unoriginal studies (e.g., review, news, editorial,
comment)
5. Studies with no outcomes of interest
6. Duplicated studies
Data extraction and management
Two reviewers (ON and SF) will independently screen
titles and abstracts of all the retrieved bibliographic
records. The eligible and ineligible criteria will be
used for each screening step. If no abstract is avail-
able, the full text will be obtained unless the article
can be confidently excluded by its title alone. If there
is any doubt whether a study should be excluded, the
study will proceed to the full-text screen to reduce
the likelihood of incorrectly excluding relevant studies.
Full text of potentially eligible studies will be independ-
ently retrieved by the two reviewers. Disagreements at
these screening levels (title/abstract and full text) will be
resolved through discussion with or adjudication by a
third reviewer (TK).
Data collection
A standard set of data will be extracted for each study
using a tailored data extraction form.
1. General study identification.
First author, year of publication, publication type,
and country where the study took place.
2. Fulfillment of eligibility criteria.
Study type, interventions, outcomes measured, and
reasons for exclusion.
3. Participants.
Number of enrolled patients, age, sex, race, KD
severity, and eligibility criteria.
4. Intervention (monoclonal antibodies).
Type of monocle antibody, dosing, frequency, timing
(as initial therapy or additional rescue therapy), and
concomitant treatment.
5. Outcomes.
Coronary diameters, coronary abnormality,
treatment resistance, adverse events, duration
of fever, duration of laboratory parameter
abnormality (e.g., CRP and/or ESR), and length
of hospital stay.
Assessment of risk of bias in included studies
The risk of bias in included studies will be assessed
using the Cochrane risk of bias tool according to the
handbook and the Risk of Bias Assessment Tool for
Non-Randomized Studies (RoBANS) for observational
studies [22, 23]. We will use the following criteria to as-
sess the risk of bias: random sequence generation, allo-
cation sequence concealment, blinding of participants
and personnel, blinding of outcome assessment, incom-
plete outcome data, selective outcome reporting, and
other biases. In addition, we will assess the method as
high risk of bias, low risk of bias, and unclear risk of
bias.
Measurement of treatment effect
Studies will be included in meta-analysis if they are of
the same type, such as RCTs or cluster RCTs, and have
the same population, intervention, comparison, and out-
comes. Evaluation of whether included studies are eli-
gible for meta-analysis will be conducted by two authors
(ON and SF), and in the event of disagreement, the dis-
agreement will be resolved through discussion with or
adjudication by a third reviewer (TK).
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We will narratively summarize the available evidence
when it is not possible to perform a meta-analysis.
1. Dichotomous data.
We will present results as summary risk ratio with
95 % confidence interval (CI) in the analysis of RCTs
and present results as odds ratio with 95 % CI in the
analysis of observational studies.
2. Continuous data.
We will use the mean difference with 95 % CIs
if outcomes were measured in the same way
between trials. We will use the standardized mean
difference with 95 % CIs to combine trials that
measured the same outcome but used different
methods.
Unit of analysis issues
1. Cluster-randomized trials.
We will include cluster-randomized trials in the
analyses along with individually randomized trials.
We will adjust their sample sizes using the methods
described in the handbook and an estimate of the
intracluster correlation coefficient (ICC) derived from
the trial (if possible), from a similar trial or from a
study of a similar population. If we use ICCs from
other sources, we will report this and conduct sensi-
tivity analyses to investigate the effect of variation in
the ICC. If we identify both cluster-randomized trials
and individually randomized trials, we plan to
synthesize the relevant information. We will consider
it reasonable to combine the results from both if there
is little heterogeneity between the study designs, and
the interaction between the effect of intervention and
the choice of randomization unit is considered to be
unlikely. We will also acknowledge heterogeneity in
the randomization unit and perform a sensitivity ana-
lysis to investigate the effects of the randomization
unit.
2. Multi-armed trials.
Multi-armed trials will be included in the analyses.
We will combine all relevant interventions into a
single group and incorporate all relevant control
groups into a single group. Any other different
interventions will be addressed in different meta-
analyses. If one of the arms is irrelevant, we will
exclude it from the analysis.
Management of missing data
Levels of attrition will be recorded for the included
studies. We will explore the impact of included stud-
ies with high levels of missing data in the primary
outcome by using sensitivity analysis. For all outcomes,
intention-to-treat (ITT) analysis will be used as much as
possible. All participants will be analyzed in the group to
which they were allocated, regardless of whether they re-
ceived the allocated intervention.
Strategy for data synthesis
Statistical analysis will be performed using Review
Manager V.5.3 (Cochrane Collaboration software). If the
collected data from included studies show statistical
homogeneity, fixed effects meta-analysis will be per-
formed. If the data are anticipated to have significant
heterogeneity between studies, we will perform random
effects meta-analyses if an average treatment effect
across trials is considered clinically meaningful. The re-
sults of the random effects model will be used as the
average range of possible intervention effects with 95 %
CIs and the estimates of I2, T2, and χ2, and the difference
in clinical implication between interventions will be dis-
cussed. Finally, we will assess the quality of the following
individual outcomes and produce summaries using the
Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) approach:
1. Coronary artery abnormalities
2. Treatment resistance
3. Incidence of adverse event
4. Duration of fever
5. Length of hospital stay
Data will be imported from RevMan 2014 to the
GRADE profiler to produce “summary of findings”
tables. These tables will include a summary of the
intervention effect and a quality of individual out-
comes using the GRADE approach. The quality of the
body of evidence for each outcome will be assessed
based on five factors and will be downgraded from
high quality by one level for serious or by two levels
for very serious limitations: study limitations, con-
sistency of effect, imprecision, indirectness, and publi-
cation bias.
Assessment of heterogeneity
We will evaluate heterogeneity in the meta-analyses
using I2, T2, and χ2 statistics. We will consider that het-
erogeneity exists if I2 is 50 % or more, T2 is greater than
0, or when the significance of χ2 is lower than 0.10.
Assessment of reporting bias
If there are sufficient studies (10 or more) in the meta-
analysis, we will investigate reporting biases (publication
biases) using funnel plots. If asymmetry is identified or
found in a visual assessment, the asymmetry will be veri-
fied using exploratory analyses.
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Subgroup analysis and investigation of heterogeneity
We will implement subgroup analyses of the following:
1. Type of monoclonal antibody: infliximab vs. others
2. Country of origin: Japan vs. other countries
3. Timing of intervention: initial therapy vs. additional
rescue therapy for IVIG non-responders
Sensitivity analysis
We will perform sensitivity analysis if the review might
affect the results due to the high risk of bias of some of
the included trials. For the purpose of this sensitivity
analysis, we will define high quality as a trial having a
low risk of random sequence generation, adequate allo-
cation concealment, and the percentage of missing data
less than 20 %, given the stated importance of attrition
as a quality measure. Only the primary outcome will be
included in the sensitivity analyses. If statistical hetero-
geneity exists in outcomes, we will carry out the sensitiv-
ity analysis to explore the effects of fixed or random
effects analyses. Furthermore, if there are any assump-
tions for ICC values used in cluster-randomized trials,
we will perform sensitivity analysis.
Discussion
This review and meta-analysis will provide evidence of
the effectiveness of monoclonal antibodies as a thera-
peutic option for KD patients. Additionally, our review
will guide the future development of clinical and basic
research in the management of KD.
Additional files
Additional file 1: PRISMA-P checklist: recommended items to address in
a systematic review protocol. (DOC 81 kb)
Additional file 2: Search terms and strategies. The search strategy
utilized is outlined in more detail in the file. (DOCX 41 kb)
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